Creative Planning Acquires 4,480 Shares of Teleflex Incorporated $TFX

Creative Planning increased its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 76.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,338 shares of the medical technology company’s stock after buying an additional 4,480 shares during the period. Creative Planning’s holdings in Teleflex were worth $1,224,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in shares of Teleflex by 242.9% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 153 shares during the period. Banque Cantonale Vaudoise bought a new position in Teleflex during the 1st quarter worth $27,000. Costello Asset Management INC acquired a new position in Teleflex during the 1st quarter worth about $28,000. Brooklyn Investment Group lifted its holdings in Teleflex by 258.6% during the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company’s stock worth $29,000 after buying an additional 150 shares during the period. Finally, True Wealth Design LLC grew its position in shares of Teleflex by 10,333.3% in the 2nd quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock valued at $37,000 after buying an additional 310 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Teleflex Stock Performance

NYSE:TFX opened at $114.42 on Friday. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a twelve month low of $102.58 and a twelve month high of $195.24. The company has a fifty day moving average of $120.31 and a 200-day moving average of $121.05. The firm has a market capitalization of $5.06 billion, a P/E ratio of 26.92, a P/E/G ratio of 1.79 and a beta of 1.05.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, November 6th. The medical technology company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.38 by $0.29. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business had revenue of $892.90 million for the quarter, compared to analyst estimates of $892.79 million. During the same period in the prior year, the firm earned $3.49 earnings per share. Teleflex’s revenue was up 19.4% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. As a group, sell-side analysts anticipate that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Friday, November 14th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Friday, November 14th. Teleflex’s payout ratio is presently -18.50%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada lowered their price objective on Teleflex from $135.00 to $120.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Wells Fargo & Company lowered their price target on shares of Teleflex from $131.00 to $114.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Truist Financial reduced their price objective on shares of Teleflex from $128.00 to $120.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Wall Street Zen downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Teleflex has an average rating of “Reduce” and an average price target of $134.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.